Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine plus lansoprazole for gastroesophageal reflux disease
IRCT20141201020178N6Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in gastroesophageal reflux disease (GERD) comparing Lansoprazole + placebo with Lansoprazole + duloxetine (2 arms). Primary endpoints: Typical symptoms of gastroesophageal reflux disease and Quality of life. Started Dec 2017; status: completed.
02
Drugs
duloxetinelansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on IRCT20141201020178N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141201020178N6.